Clinical and research issues regarding chronic advanced coronary artery disease. Part I: Contemporary and emerging therapies

American Heart Journal

Volumn 155, Issue 3, 2008, Pages 418-434

  Jolicoeur, E Marc ^a,f   Granger, Christopher B ^a,f   Henry, Timothy D ^b,f   Holmes, David J ^c,f   Pepine, Carl J ^d,f   Mark, Daniel ^a,f   Chaitman, Bernard R ^e,f   Gersh, Bernard J ^c,f   Ohman, E Magnus ^a,f  

^a DUKE UNIVERSITY   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Mayo Clinic and Foundation ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMLODIPINE; ANTIOXIDANT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CLOPIDOGREL; DILTIAZEM; EDETIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NADOLOL; NICORANDIL; NITRATE; OPIATE DERIVATIVE; PLASMID DNA; PROPRANOLOL DERIVATIVE; RANOLAZINE; TORCETRAPID; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLEEDING; BLOOD PRESSURE; CARDIOVASCULAR GENE THERAPY; CELL THERAPY; CHELATION THERAPY; CHRONIC DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; CORONARY STENT; COUNTERPULSATION; DISORIENTATION; DRUG WITHDRAWAL; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; MORTALITY; NAUSEA; NEUROMODULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECANALIZATION; SIDE EFFECT; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

BIOMEDICAL RESEARCH; CHRONIC DISEASE; CONGRESSES AS TOPIC; CORONARY DISEASE; DECISION MAKING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 39549116947     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.12.004     Document Type: Article

References (135)

1. Fox K., Garcia M.A., Ardissino D., et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 27 (2006) 1341-1381
2. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 107 (2003) 149-158
3. Opie L.H., Commerford P.J., and Gersh B.J. Controversies in stable coronary artery disease. Lancet 367 (2006) 69-78
4. Mannheimer C., Camici P., Chester M.R., et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 23 (2002) 355-370
5. Mukherjee D, Bhatt DL, Roe MT, et al. Direct myocardial revascularization and angiogenesis-how many patients might be eligible? Am J Cardiol 1999;84:598-600, A8.
6. Bernstein S.J., Brorsson B., Aberg T., et al. Appropriateness of referral of coronary angiography patients in Sweden. SECOR/SBU Project Group. Heart 81 (1999) 470-477
7. Brorsson B., Bernstein S.J., Brook R.H., et al. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 87 (2002) 140-145
8. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
9. Aaberge L., Nordstrand K., Dragsund M., et al. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris: clinical results from The Norwegian Randomized Trial. J Am Coll Cardiol 35 (2000) 1170-1177
10. Allen K.B., Dowling R.D., Fudge T.L., et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 341 (1999) 1029-1036
11. Burkhoff D., Schmidt S., Schulman S.P., et al. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. Lancet 354 (1999) 885-890
12. Frazier O.H., March R.J., Horvath K.A., et al. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 341 (1999) 1021-1028
13. Leon M.B., Kornowski R., Downey W.E., et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 46 (2005) 1812-1819
14. Oesterle S.N., Sanborn T.A., Ali N., et al. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Lancet 356 (2000) 1705-1710
15. Schofield P.M., Sharples L.D., Caine N., et al. Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial. Lancet 353 (1999) 519-524
16. Henry T.D., Annex B.H., McKendall G.R., et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107 (2003) 1359-1365
17. Kastrup J., Jorgensen E., Ruck A., et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 45 (2005) 982-988
18. Stewart D.J., Hilton J.D., Arnold J.M., et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 13 (2006) 1503-1511
19. Simons M., Annex B.H., Laham R.J., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105 (2002) 788-793
20. Losordo D.W., Vale P.R., Hendel R.C., et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105 (2002) 2012-2018
21. Henry T.D., Grines C.L., Watkins M.W., et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 50 (2007) 1038-1046
22. Kandzari D.E., Lam L.C., Eisenstein E.L., et al. Advanced coronary artery disease: appropriate end points for trials of novel therapies. Am Heart J 142 (2001) 843-851
23. Henry T.D., Satran D., Johnson R.J., et al. Natural history of patients with refractory angina. J Am Coll Cardiol 47 (2006) 231
24. Mouallem M., Schwartz E., and Farfel Z. Prolonged oral morphine therapy for severe angina pectoris. J Pain Symptom Manage 19 (2000) 393-397
25. Uen S., Un I., Fimmers R., et al. Myocardial ischemia during everyday life in patients with arterial hypertension: prevalence, risk factors, triggering mechanism and circadian variability. Blood Press Monit 11 (2006) 173-182
26. Smolensky M.H., and Portaluppi F. Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease. Am Heart J 137 4 Pt. 2 (1999) S14-S24
27. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
28. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
29. Bhatt D.L., Fox K.A.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
30. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
31. Claeys M.J., Cosyns B., Hoffer E., et al. Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease. Acta Cardiol 59 (2004) 269-274
32. Calabro P., and Yeh E.T. The pleiotropic effects of statins. Curr Opin Cardiol 20 (2005) 541-546
33. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
34. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
35. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
36. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682
37. Deedwania P., Stone P.H., Bairey C.N., et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115 (2007) 700-707
38. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
39. McCormack J.G., Barr R.L., Wolff A.A., et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93 (1996) 135-142
40. Wolff A.A., Rotmensch H.H., Stanley W.C., et al. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev 7 (2002) 187-203
41. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291 (2004) 309-316
42. Zerumsky K., and McBride B.F. Ranolazine in the management of chronic stable angina. Am J Health Syst Pharm 63 (2006) 2331-2338
43. Antzelevitch C., Belardinelli L., Zygmunt A.C., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910
44. Belardinelli L., Shryock J.C., and Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 Suppl 4 (2006) iv6-iv14
45. Eng S., Maddaford T.G., Kardami E., et al. Protection against myocardial ischemic/reperfusion injury by inhibitors of two separate pathways of Na+ entry. J Mol Cell Cardiol 30 (1998) 829-835
46. Eigel B.N., and Hadley R.W. Contribution of the Na(+) channel and Na(+)/H(+) exchanger to the anoxic rise of [Na(+)] in ventricular myocytes. Am J Physiol 277 5 Pt. 2 (1999) H1817-H1822
47. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43 (2004) 1375-1382
48. Hung J., Lamb I.H., Connolly S.J., et al. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. Circulation 68 (1983) 560-567
49. Pehrsson S.K., Ringqvist I., Ekdahl S., et al. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clin Cardiol 23 (2000) 763-770
50. Fox K.M., Mulcahy D., Findlay I., et al. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 17 (1996) 96-103
51. Stone P.H., Gratsiansky N.A., Blokhin A., et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48 (2006) 566-575
52. Koren M.J., Crager M.R., and Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 49 (2007) 1027-1034
53. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297 (2007) 1775-1783
54. O'Meara E., and McMurray J.J.V. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?. Heart 91 (2005) 131-132
55. Sorensen H.T., Rasmussen H.H., Moller-Petersen J.F., et al. Epidemiology of pain requiring strong analgesics outside hospital in a geographically defined population in Denmark. Dan Med Bull 39 (1992) 464-467
56. Ballantyne J.C., and Mao J. Opioid therapy for chronic pain. N Engl J Med 349 (2003) 1943-1953
57. Stone G.W., Kandzari D.E., Mehran R., et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation 112 (2005) 2364-2372
58. Srinivas V.S., Brooks M.M., Detre K.M., et al. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation 106 (2002) 1627-1633
59. Hochman J.S., Lamas G.A., Buller C.E., et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 355 (2006) 2395-2407
60. Suero J.A., Marso S.P., Jones P.G., et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 38 (2001) 409-414
61. Prasad A., Rihal C.S., Lennon R.J., et al. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol 49 (2007) 1611-1618
62. Abbott J.D., Kip K.E., Vlachos H.A., et al. Recent trends in the percutaneous treatment of chronic total coronary occlusions. Am J Cardiol 97 (2006) 1691-1696
63. Olivari Z., Rubartelli P., Piscione F., et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol 41 (2003) 1672-1678
64. Ruocco Jr. N.A., Ring M.E., Holubkov R., et al. Results of coronary angioplasty of chronic total occlusions (the National Heart, Lung, and Blood Institute 1985-1986 Percutaneous Transluminal Angioplasty Registry). Am J Cardiol 69 (1992) 69-76
65. Stone G.W., Reifart N.J., Moussa I., et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 112 (2005) 2530-2537
66. Contreras G., Cieza T., Hardy N., et al. Uncrossable coronary obstruction treated by the new laser guidewire. J Invasive Cardiol 17 (2005) 560-562
67. Abbas A.E., Brewington S.D., Dixon S.R., et al. Intracoronary fibrin-specific thrombolytic infusion facilitates percutaneous recanalization of chronic total occlusion. J Am Coll Cardiol 46 (2005) 793-798
68. Strauss B.H., Goldman L., Qiang B., et al. Collagenase plaque digestion for facilitating guide wire crossing in chronic total occlusions. Circulation 108 (2003) 1259-1262
69. Sinvhal R.M., Gowda R.M., and Khan I.A. Enhanced external counterpulsation for refractory angina pectoris. Heart 89 (2003) 830-833
70. Arora R.R., Chou T.M., Jain D., et al. The Multicenter Study of Enhanced External Counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 33 (1999) 1833-1840
71. Niebauer J., and Cooke J.P. Cardiovascular effects of exercise: role of endothelial shear stress. J Am Coll Cardiol 28 (1996) 1652-1660
72. Michaels A.D., Raisinghani A., Soran O., et al. The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study. Am Heart J 150 (2005) 1066-1073
73. Lawson W.E., Hui J.C., Zheng Z.S., et al. Improved exercise tolerance following enhanced external counterpulsation: cardiac or peripheral effect?. Cardiology 87 (1996) 271-275
74. Urano H., Ikeda H., Ueno T., et al. Enhanced external counterpulsation improves exercise tolerance, reduces exercise-induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease. J Am Coll Cardiol 37 (2001) 93-99
75. Masuda D., Nohara R., Hirai T., et al. Enhanced external counterpulsation improved myocardial perfusion and coronary flow reserve in patients with chronic stable angina; evaluation by(13)N-ammonia positron emission tomography. Eur Heart J 22 (2001) 1451-1458
76. Wu G., Du Z., Hu C., et al. Angiogenic effects of long-term enhanced external counterpulsation in a dog model of myocardial infarction. Am J Physiol Heart Circ Physiol 290 (2006) H248-H254
77. Lawson W.E., Hui J.C., and Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology 94 (2000) 31-35
78. Peterson P.N., Spertus J.A., Magid D.J., et al. The impact of diabetes on one-year health status outcomes following acute coronary syndromes. BMC Cardiovasc Disord 6 (2006) 41
79. Soran O., Kennard E.D., Kfoury A.G., et al. Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry). Am J Cardiol 97 (2006) 17-20
80. Michaels A.D., McCullough P.A., Soran O.Z., et al. Primer: practical approach to the selection of patients for and application of EECP. Nat Clin Pract Cardiovasc Med 3 (2006) 623-632
81. Oakley J.C., and Prager J.P. Spinal cord stimulation: mechanisms of action. Spine 27 (2002) 2574-2583
82. Hautvast R.W., De Jongste M.J., Staal M.J., et al. Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study. Am Heart J 136 (1998) 1114-1120
83. McNab D., Khan S.N., Sharples L.D., et al. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial. Eur Heart J 27 (2006) 1048-1053
84. Buchser E., Durrer A., and Albrecht E. Spinal cord stimulation for the management of refractory angina pectoris. J Pain Symptom Manage 31 4 Suppl (2006) S36-S42
85. Issa Z.F., Zhou X., Ujhelyi M.R., et al. Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmias in a postinfarction heart failure canine model. Circulation 111 (2005) 3217-3220
86. STARTSTIM (Stimulation Therapy for Angina Refractory To Standard Treatments, Interventions and Medications) www.clinicaltrial.gov (id: NCT00200070). Last access on 10/10/2007.
87. Tardif J.C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26 (2005) 2529-2536
88. Nishida T., Shimokawa H., Oi K., et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 110 (2004) 3055-3061
89. The IONA Investogators. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359 (2002) 1269-1275
90. Ciapponi A., Pizarro R., and Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev (2005) CD003614
91. Lee L., Horowitz J., and Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 25 (2004) 634-641
92. Henry T.D. Therapeutic angiogenesis. BMJ 318 (1999) 1536-1539
93. Laitinen M., Hartikainen J., Hiltunen M.O., et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 11 (2000) 263-270
94. Grines C.L., Watkins M.W., Helmer G., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105 (2002) 1291-1297
95. Grines C.L., Watkins M.W., Mahmarian J.J., et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 42 (2003) 1339-1347
96. Hedman M., Hartikainen J., Syvanne M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107 (2003) 2677-2683
97. Gyongyosi M., Khorsand A., Zamini S., et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112 9 Suppl (2005) I157-I165
98. Penny W.F., and Hammond H.K. Clinical use of intracoronary gene transfer of fibroblast growth factor for coronary artery disease. Curr Gene Ther 4 (2004) 225-230
99. Staudacher D.L., Preis M., Lewis B.S., et al. Cellular and molecular therapeutic modalities for arterial obstructive syndromes. Pharmacol Ther 109 (2006) 263-273
100. Muller O.J., Katus H.A., and Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 73 (2007) 453-462
101. Tomanek R.J., Sandra A., Zheng W., et al. Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis. Circ Res 88 (2001) 1135-1141
102. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 13 (2002) 3-13
103. Kinnaird T., Stabile E., Burnett M.S., et al. Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res 95 (2004) 354-363
104. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7 (2001) 430-436
105. Kinnaird T., Stabile E., Burnett M.S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94 (2004) 678-685
106. Kinnaird T., Stabile E., Burnett M.S., et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109 (2004) 1543-1549
107. Jolicoeur E.M., Granger C.B., Fakunding J.L., et al. Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. Am Heart J 153 (2007) 732-742
108. Siminiak T., Fiszer D., Jerzykowska O., et al. Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur Heart J 26 (2005) 1188-1195
109. Hagege A.A., Marolleau J.P., Vilquin J.T., et al. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation 114 1 Suppl (2006) I108-I113
110. Menasche P., Hagege A.A., Scorsin M., et al. Myoblast transplantation for heart failure. Lancet 357 (2001) 279-280
111. Mills J.M., Adam G.L., Tricoci P., et al. Highlights from the 20th Scientific Sessions of the American Heart Association: November 12 to 15, 2006, Chicago, Illinois. Am Heart J 153 (2007) 213-223
112. Fuchs S., Satler L.F., Kornowski R., et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol 41 (2003) 1721-1724
113. Perin E.C., Dohmann H.F., Borojevic R., et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107 (2003) 2294-2302
114. Tse H.F., Kwong Y.L., Chan J.K., et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361 (2003) 47-49
115. Losordo D.W., Schatz R.A., White C.J., et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 115 (2007) 3165-3172
116. Wilson R.F., and Henry T.D. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: double-edged swords. J Am Coll Cardiol 46 (2005) 1649-1650
117. Erbs S., Linke A., Adams V., et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res 97 (2005) 756-762
118. Mangi A.A., Noiseux N., Kong D., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9 (2003) 1195-1201
119. Eliopoulos N., Al-Khaldi A., Crosato M., et al. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 10 (2003) 478-489
120. Grier M.T., and Meyers D.G. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 27 (1993) 1504-1509
121. Lamb D.J., and Leake D.S. The effect of EDTA on the oxidation of low density lipoprotein. Atherosclerosis 94 (1992) 35-42
122. Klatt P., and Esterbauer H. Oxidative hypothesis of atherogenesis. J Cardiovasc Risk 3 (1996) 346-351
123. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
124. Bukoski R.D., Ishibashi K., and Bian K. Vascular actions of the calcium-regulating hormones. Semin Nephrol 15 (1995) 536-549
125. Meltzer L.E., Kitchell J.R., and Palmon Jr. F. The long term use, side effects, and toxicity of disodium ethylenediamine tetraacetic acid (EDTA). Am J Med Sci 242 (1961) 11-17
126. Catherwood B.D., Titus L., Evans C.O., et al. Increased expression of tissue plasminogen activator messenger ribonucleic acid is an immediate response to parathyroid hormone in neonatal rat osteoblasts. Endocrinology 134 (1994) 1429-1436
127. Leloup G., Delaisse J.M., and Vaes G. Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones. J Bone Miner Res 9 (1994) 891-902
128. Knudtson M.L., Wyse D.G., Galbraith P.D., et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA 287 (2002) 481-486
129. Ernst E. Chelation therapy for coronary heart disease: an overview of all clinical investigations. Am Heart J 140 (2000) 139-141
130. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis (2007) In press
131. Adams G.L., Mills J.S., Melloni C., et al. Highlights from the 56th Annual Scientific Sessions of the American College of Cardiology: March 25 to 27, 2007, Atlanta, Georgia. Am Heart J 154 (2007) 247-259
132. Oesterle S.N., Reifart N., Hauptmann E., et al. Percutaneous in situ coronary venous arterialization: report of the first human catheter-based coronary artery bypass. Circulation 103 (2001) 2539-2543
133. Oesterle S.N., Reifart N., Hayase M., et al. Catheter-based coronary bypass: a development update. Catheter Cardiovasc Interv 58 (2003) 212-218
134. Robertson H.F. The reestablishment of cardiac circulation during progressive coronary occlusion: an experimental study on dogs. Am Heart J 10 (1935) 533-541
135. Banai S., Ben M.S., Parikh K.H., et al. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol 49 (2007) 1783-1789